Lutetium-177 (Lu-177)-labelled radioligand therapies (RLT) targeting prostate-specific membrane antigen (PSMA) present a promising treatment for patients with progressive metastasized castration-resistant prostate cancer (mCRPC). Personalized dosimetry. facilitated by post-therapeutic imaging. offers the potential to enhance treatment efficacy by customizing radiation doses to individ... https://www.lightemupsequences.com/deal-find-W2-32-p39812-quick-super/